Purpose of Review: The treatment of stage III N2 non-small cell lung cancer (NSCLC) remains debated. There is an absence of a universally agreed definition of resectability for this heterogeneous group and a lack of trial data. Recent Findings: We reviewed and compared current international guidelines and evidence surrounding management of stage III N2 NSCLC. The Irish and Australian guidelines advise subcategorising N2 disease into N2a (may be resectable) and N2b (never resectable). On the contrary, American and British guidelines avoid subcategorising N2 disease, emphasising importance of local MDT decisions. It is suggested that evidence for resection of stage III tumours is relatively weak, but that stage IIIA should generally be considered for resection, and stage IIIB is not recommended for resection. For resectable disease, surgery may be combined with neoadjuvant chemoimmunotherapy, or adjuvant chemotherapy followed by immunotherapy and radiotherapy in selected patients. Summary: There is some evidence that technically resectable disease can be treated solely with radiotherapy with similar outcomes to resection. In the event of unresectable disease, chemoradiotherapy has been the traditional management option. However, recent studies with chemoradiotherapy alongside immunotherapy appear promising. There are many factors that influence the treatment pathway offered to patients with stage III N2 NSCLC, including patient factors, team expertise, and local resources. Therefore, the role of MDTs in defining resectability and formulating an individualised treatment plan is crucial.
12 September 2024 in The Lancet Regional Health - Southeast Asia
Metastatic spinal cord compression (MSCC) is a common complication in cancer patients, occurring in 3–5% of diagnosed cases annually, and serves as the initial manifestation of malignancy in 20% of patients. Timely diagnosis and management are critical due to the risk of irreversible neurological damage and the significant impact on both quality and quantity of life. The National Institute for Health and Care Excellence (NICE) recommends that patients presenting with back pain accompanied by neurological signs and/or symptoms undergo whole-spine magnetic resonance imaging (MRI) within 24 h. This retrospective study at Medway Maritime Hospital in England aimed to assess adherence to these guidelines by reviewing the time from presentation to MRI for patients exhibiting symptoms and/or signs of MSCC. Data for 69 patients were collected over one year using electronic patient records and the acute oncology service database. Analysis revealed that MRI was conducted within 24 h in only 43 out of 69 cases (62%), and 16 out of 25 delayed cases (i.e., MRI done beyond the recommended 24 h window) experienced delays of more than 48 h. To improve guideline adherence, interventions such as informational flyers and regular MSCC training sessions, including trainee teaching and presentations during grand rounds, were implemented. A follow-up re-audit involving 113 patients over one year demonstrated improved adherence to the 24 h MRI guideline, with 81 out of 113 cases (71%) meeting the target. The second cycle also documented reasons for delays, identifying patient compliance and pain control as primary factors. Additionally, the timing of steroid administration following suspicion of MSCC was recorded. Future studies should re-assess adherence, focus on better documentation of delay causes, enhance pain management before MRI scans, and ensure prompt steroid administration.
21 April 2023 in Journal of Cancer Research and Therapeutics
We report a very rare case of clear cell variant of renal cell carcinoma (RCC) in a 3-year-old male child, who presented to us with a left-sided lump in his abdomen. Computed tomography (CT) scan and technetium-99 Dimercapto succinic acid (DMSA) scan revealed a large left renal mass with compromised left renal function. Left-sided nephroureterectomy was done and histopathology demonstrated clear cell carcinoma, possibly translocation-associated RCC (miT family) staged as pT2NxMx. Postoperative CT scans of the thorax and whole abdomen showed secondaries in the lungs and liver. We discussed treatment options in a multidisciplinary tumor board but meanwhile the child succumbed to respiratory failure.
Background: Metaplastic Breast Cancer (MpBC) is an exceedingly rare entity, accounting for less than 1% of all malignant breast tumours. Predominantly triple‐negative, they are notorious for their chemoresistance, high rates of recurrence and decreased disease‐free survival (DFS). All this contributes significantly to BC mortality and results in poor prognostic implications. Limited evidence has led to a lacuna of specific treatment guidelines for this entity and hence remains an uncharted territory for clinicians.Case: We report a case of a 46 year old premenopausal female with left‐sided metaplastic triple negative T3N2aM0 BC with mesenchymal differentiation (high grade) whom we treated with neoadjuvant chemotherapy, primary surgery in the form of extreme oncoplasty and adjuvant radiotherapy by Telecobalt machine. Contrary to the expected aggressive course of the disease and poor prognosis of treatment, the patient is presently in remission without progression for over 2 years of follow up.Conclusion: Limited experience in management of this pathological entity warrants the need for more research on it, with a special focus on targeted therapy. Discussing possibilities of a tailored approach, rather than a one‐size‐fits‐all approach may aid in paving the path for the future of MpBC treatment.
Background : Metaplastic Breast Cancer (MpBC) is an exceedingly rare entity, accounting for less than 1% of all malignant breast tumours. Predominantly triple-negative, they are notorious for their chemoresistance, high rates of recurrence and decreased disease-free survival (DFS). All this contributes significantly to BC mortality and results in poor prognostic implications. Limited evidence has led to a lacuna of specific treatment guidelines for this entity and hence remains an uncharted territory for clinicians. Case : We report a case of left-sided low-grade metaplastic triple negative T3N2aM0 BC treated with neoadjuvant chemotherapy, primary surgery, and adjuvant radiotherapy, presently in remission. Conclusion : Limited experience in management of this pathological entity warrants the need for more research on it, with a special focus on targeted therapy. Discussing possibilities of a tailored approach, rather than a one-size-fits-all approach may aid in paving the path for the future of MpBC treatment.